MRSN logo

Mersana Therapeutics (MRSN) EBITDA

Annual EBITDA

-$166.08 M
+$33.88 M+16.94%

December 31, 2023

Summary

Performance

1-Year Change

+16.94%

3-Year Change

-91.61%

5-Year Change

-163.62%

15-Year Change

-339.61%

MRSN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

10.14%
MRSN annual EBITDA is higher than 10.14% of companies in Healthcare sector

High & Low

All-time High

-$13.17 M

3-Year Low

-$199.96 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
MRSN previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
MRSN next annual earnings announcement is scheduled for Feb 28, 2025

OtherMRSNprofitabilitymetrics:

Annual Revenue

$36.85 M
MRSN annual revenue is $36.85 million

Annual Net Income

-$171.67 M
MRSN annual net profit is -$171.67 million

Annual EBIT

-$167.60 M
MRSN annual earnings before interest & taxes is -$167.60 million

Annual EPS

-$1.48
MRSN annual earnings per share is -$1.48

Quarterly EBITDA

-$9.70 M
+$13.19 M+57.63%

September 30, 2024

Summary

Performance

3-Month Change

+57.63%

1-Year Change

+75.89%

3-Year Change

+75.89%

5-Year Change

+75.89%

MRSN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

36.53%
MRSN quarterly EBITDA is higher than 36.53% of companies in Healthcare sector

High & Low

All-time High

$22.24 M
MRSN quarterly EBITDA is currently -143.60% below its historical high of $22.24 million

3-Year Low

-$58.72 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MRSN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
MRSN next earnings announcement is scheduled for Feb 28, 2025

OtherMRSNprofitabilitymetrics:

Quarterly Revenue

$12.60 M
MRSN quarterly revenue is $12.60 million

Quarterly Net Income

-$11.50 M
MRSN quarterly net profit is -$11.50 million

Quarterly EBIT

-$10.10 M
MRSN quarterly earnings before interest & taxes is -$10.10 million

Quarterly EPS

-$0.09
MRSN quarterly earnings per share is -$0.09

TTM EBITDA

-$68.51 M
+$30.52 M+30.82%

September 30, 2024

Summary

Performance

3-Month Change

+30.82%

1-Year Change

+64.27%

3-Year Change

+64.27%

5-Year Change

+64.27%

MRSN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

25.42%
MRSN TTM EBITDA is higher than 25.42% of companies in Healthcare sector

High & Low

All-time High

-$5.25 M

3-Year Low

-$210.22 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
MRSN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
MRSN next earnings announcement is scheduled for Feb 28, 2025

OtherMRSNprofitabilitymetrics:

TTM Revenue

$34.84 M
MRSN TTM revenue is $34.84 million

TTM Net Income

-$74.62 M
MRSN TTM net profit is -$74.62 million

TTM EBIT

-$70.18 M
MRSN TTM earnings before interest & taxes is -$70.18 million

TTM EPS

-$0.61
MRSN TTM earnings per share is -$0.61

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$166.08 M
MRSN annual EBITDA is -$166.08 million

Annual Net Income

-$171.67 M
MRSN annual net profit is -$171.67 million

Annual Interest Expense

$4.07 M
MRSN annual interest expense is $4.07 million

Annual Income Tax

-
MRSN annual income tax value is unknown

Annual D&A

$1.52 M
MRSN annual depreciation & amortization is $1.52 million

MRSN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+16.9%+75.9%+64.3%
3 y3 years-91.6%+75.9%+64.3%
5 y5 years-163.6%+75.9%+64.3%

MRSN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+16.9%at high+83.5%at high+67.4%
5 y5-year-521.4%+16.9%at high+83.5%-156.3%+67.4%
alltimeall time-1161.4%+16.9%-143.6%+83.5%-1206.1%+67.4%

Mersana Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$9.70 M(-57.6%)
-$68.51 M(-30.8%)
Jun 2024
-
-$22.88 M(+28.0%)
-$99.02 M(-23.3%)
Mar 2024
-
-$17.88 M(-0.9%)
-$129.10 M(-22.3%)
Dec 2023
-$166.08 M(-16.9%)
-$18.05 M(-55.1%)
-$166.08 M(-13.4%)
Sep 2023
-
-$40.21 M(-24.1%)
-$191.71 M(-8.8%)
Jun 2023
-
-$52.96 M(-3.5%)
-$210.22 M(+0.8%)
Mar 2023
-
-$54.86 M(+25.6%)
-$208.49 M(+4.3%)
Dec 2022
-$199.96 M(+19.1%)
-$43.68 M(-25.6%)
-$199.96 M(-2.0%)
Sep 2022
-
-$58.72 M(+14.6%)
-$204.07 M(+7.1%)
Jun 2022
-
-$51.23 M(+10.6%)
-$190.51 M(+5.9%)
Mar 2022
-
-$46.33 M(-3.1%)
-$179.89 M(+7.1%)
Dec 2021
-$167.94 M(+93.8%)
-$47.79 M(+5.8%)
-$167.94 M(+13.0%)
Sep 2021
-
-$45.16 M(+11.2%)
-$148.64 M(+18.3%)
Jun 2021
-
-$40.61 M(+18.1%)
-$125.62 M(+20.3%)
Mar 2021
-
-$34.37 M(+20.7%)
-$104.46 M(+20.5%)
Dec 2020
-$86.68 M
-$28.49 M(+28.7%)
-$86.67 M(+17.0%)
Sep 2020
-
-$22.14 M(+13.8%)
-$74.06 M(+8.4%)
Jun 2020
-
-$19.45 M(+17.3%)
-$68.29 M(+4.2%)
DateAnnualQuarterlyTTM
Mar 2020
-
-$16.59 M(+4.5%)
-$65.56 M(+145.3%)
Dec 2019
-$26.73 M(-57.6%)
-$15.88 M(-3.0%)
-$26.73 M(-18.8%)
Sep 2019
-
-$16.38 M(-2.0%)
-$32.93 M(-1.1%)
Jun 2019
-
-$16.71 M(-175.2%)
-$33.29 M(+16.3%)
Mar 2019
-
$22.24 M(-200.7%)
-$28.62 M(-54.8%)
Dec 2018
-$63.00 M(+66.8%)
-$22.08 M(+32.0%)
-$63.36 M(+16.3%)
Sep 2018
-
-$16.73 M(+38.8%)
-$54.46 M(+19.6%)
Jun 2018
-
-$12.05 M(-3.7%)
-$45.55 M(+7.5%)
Mar 2018
-
-$12.51 M(-5.2%)
-$42.38 M(+12.2%)
Dec 2017
-$37.78 M(+186.9%)
-$13.19 M(+68.7%)
-$37.78 M(+63.0%)
Sep 2017
-
-$7.82 M(-11.9%)
-$23.18 M(+10.0%)
Jun 2017
-
-$8.88 M(+12.3%)
-$21.07 M(+33.1%)
Mar 2017
-
-$7.90 M(-657.7%)
-$15.82 M(+20.2%)
Dec 2016
-$13.17 M(-17.9%)
$1.42 M(-124.8%)
-$13.17 M(-9.7%)
Sep 2016
-
-$5.71 M(+57.1%)
-$14.58 M(+64.3%)
Jun 2016
-
-$3.63 M(-30.8%)
-$8.88 M(+69.2%)
Mar 2016
-
-$5.25 M
-$5.25 M
Dec 2015
-$16.04 M
-
-

FAQ

  • What is Mersana Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Mersana Therapeutics?
  • What is Mersana Therapeutics annual EBITDA year-on-year change?
  • What is Mersana Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Mersana Therapeutics?
  • What is Mersana Therapeutics quarterly EBITDA year-on-year change?
  • What is Mersana Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Mersana Therapeutics?
  • What is Mersana Therapeutics TTM EBITDA year-on-year change?

What is Mersana Therapeutics annual EBITDA?

The current annual EBITDA of MRSN is -$166.08 M

What is the all time high annual EBITDA for Mersana Therapeutics?

Mersana Therapeutics all-time high annual EBITDA is -$13.17 M

What is Mersana Therapeutics annual EBITDA year-on-year change?

Over the past year, MRSN annual EBITDA has changed by +$33.88 M (+16.94%)

What is Mersana Therapeutics quarterly EBITDA?

The current quarterly EBITDA of MRSN is -$9.70 M

What is the all time high quarterly EBITDA for Mersana Therapeutics?

Mersana Therapeutics all-time high quarterly EBITDA is $22.24 M

What is Mersana Therapeutics quarterly EBITDA year-on-year change?

Over the past year, MRSN quarterly EBITDA has changed by +$30.52 M (+75.89%)

What is Mersana Therapeutics TTM EBITDA?

The current TTM EBITDA of MRSN is -$68.51 M

What is the all time high TTM EBITDA for Mersana Therapeutics?

Mersana Therapeutics all-time high TTM EBITDA is -$5.25 M

What is Mersana Therapeutics TTM EBITDA year-on-year change?

Over the past year, MRSN TTM EBITDA has changed by +$123.20 M (+64.27%)